BG101500A - The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease - Google Patents

The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease

Info

Publication number
BG101500A
BG101500A BG101500A BG10150097A BG101500A BG 101500 A BG101500 A BG 101500A BG 101500 A BG101500 A BG 101500A BG 10150097 A BG10150097 A BG 10150097A BG 101500 A BG101500 A BG 101500A
Authority
BG
Bulgaria
Prior art keywords
alpha
disease
alzheimer
acetonitrile
amyloidene
Prior art date
Application number
BG101500A
Other languages
Bulgarian (bg)
English (en)
Inventor
Roger Markwell
Julie Hawkins
Carol Gray
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG101500A publication Critical patent/BG101500A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG101500A 1994-10-25 1997-05-20 The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease BG101500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (1)

Publication Number Publication Date
BG101500A true BG101500A (en) 1998-01-30

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101500A BG101500A (en) 1994-10-25 1997-05-20 The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease

Country Status (22)

Country Link
US (1) US5891887A (de)
EP (1) EP0786998B1 (de)
JP (1) JPH10509697A (de)
KR (1) KR100393365B1 (de)
CN (1) CN1085529C (de)
AT (1) ATE214926T1 (de)
AU (1) AU698695B2 (de)
BG (1) BG101500A (de)
BR (1) BR9509433A (de)
CZ (1) CZ287370B6 (de)
DE (1) DE69526102T2 (de)
DK (1) DK0786998T3 (de)
ES (1) ES2173977T3 (de)
GB (1) GB9421472D0 (de)
HK (1) HK1002057A1 (de)
HU (1) HUT77007A (de)
NO (1) NO312055B1 (de)
NZ (1) NZ295155A (de)
PT (1) PT786998E (de)
SK (1) SK50497A3 (de)
WO (1) WO1996012486A1 (de)
ZA (1) ZA958946B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
IL138192A0 (en) 1998-03-11 2001-11-25 Smithkline Beecham Plc Controlled release oral dosage forms
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803B1 (de) * 1989-04-13 2004-06-16 Beecham Group p.l.c. Chemische Verbindungen
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HK1002057A1 (en) 1998-07-31
AU3843195A (en) 1996-05-15
HUT77007A (hu) 1998-03-02
NZ295155A (en) 2000-07-28
GB9421472D0 (en) 1994-12-07
CN1085529C (zh) 2002-05-29
ES2173977T3 (es) 2002-11-01
ZA958946B (en) 1996-08-20
NO971899L (no) 1997-04-24
DE69526102T2 (de) 2002-10-31
NO971899D0 (no) 1997-04-24
BR9509433A (pt) 1997-09-16
ATE214926T1 (de) 2002-04-15
KR100393365B1 (ko) 2003-12-18
DK0786998T3 (da) 2002-07-15
EP0786998A1 (de) 1997-08-06
CZ125197A3 (en) 1997-07-16
EP0786998B1 (de) 2002-03-27
CN1170365A (zh) 1998-01-14
KR970706816A (ko) 1997-12-01
SK50497A3 (en) 1997-09-10
CZ287370B6 (en) 2000-11-15
NO312055B1 (no) 2002-03-11
WO1996012486A1 (en) 1996-05-02
AU698695B2 (en) 1998-11-05
DE69526102D1 (de) 2002-05-02
MX9703077A (es) 1997-07-31
JPH10509697A (ja) 1998-09-22
PT786998E (pt) 2002-09-30
US5891887A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
GR3030867T3 (en) Guanidine derivatives useful in therapy
AU4515985A (en) New tetrapyrrole therapeutic agents
HRP920667B1 (en) Application of fultripine active substance for preventing muscle deformation
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
NL300382I2 (en) Treatment of Pompe's disease
UA39936C2 (uk) 2-(2,6-дифторфеніл)-4-(2-етокси-4-трет-бутилфеніл)-2-оксазолін, спосіб мiтицидної обробки та мiтицидна композиція
AU1808488A (en) Compounds for the treatment of alzheimer's disease
UA29464C2 (uk) Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
BG101500A (en) The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
GR3032041T3 (en) Idebenone compositions for treating Alzheimer's disease.
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
SG39892G (en) 4,5-dihydro-oxazole derivatives,process for their preparation and their use
LTIP1534A (en) Medicinal preparations for prophylaxis and treating metabolic disturbance of lipoids and cholesterin
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
AU1807592A (en) New combination preparation for treatment of parkinson's disease
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
ES2146530A1 (es) Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
UA28288A (uk) Спосіб лікування шизофренії
Ananth et al. The place of loxapine: A new neurological drug.
MX9703359A (es) Acidos 2,2-dicloroalcancarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar resistencia a la insulina.
HK1021685A1 (en) Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
GB9017746D0 (en) Composition for treatment of respiratory ailments